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Myeloid-derived suppressor cells (MDSCs) and can-
cer stem cells (CSCs) are important cellular compo-
nents in the cancermicroenvironment andmay affect
cancer phenotype and patient outcome. The nature
of MDSCs and their interaction with CSCs in ovarian
carcinoma are unclear. We examined the interaction
between MDSCs and CSCs in patients with ovarian
carcinoma and showed that MDSCs inhibited T cell
activation and enhanced CSC gene expression,
sphere formation, and cancer metastasis. MDSCs
triggered miRNA101 expression in cancer cells.
miRNA101 subsequently repressesed the core-
pressor gene C-terminal binding protein-2 (CtBP2),
and CtBP2 directly targeted stem cell core genes re-
sulting in increased cancer cell stemness and
increasing metastatic and tumorigenic potential.
Increased MDSC density and tumor microRNA101
expression predict poor survival, as does decreased
tumor CtBP2 expression, independent of each other.
Collectively, our work identifies an immune-associ-
ated cellular, molecular, and clinical network
involving MDSCs-microRNA101-CtBP2-stem cell
core genes, which extrinsically controls cancer stem-
ness and impacts patient outcome.
INTRODUCTION
Death rates attributable to ovarian cancer have not changed
significantly for decades. Although ovarian cancer patients’
initial response to surgical debulking and chemotherapy is often
excellent, relapse with drug-resistant cancer usually occurs andImpatients succumb to their disease. Given our failure to improve
long-term survival from ovarian cancer, there is a need to
address the key cellular and molecular mechanisms by which
tumor metastasis and chemoresistance occur in these patients
from a novel angle.
The tumormicroenvironment is the primary arenawhere tumor
cells and the host immune system interact. The capacity of
immunity to modulate cancer phenotype including cancer
dormancy has been the subject of intensive investigation (Mat-
sushita et al., 2012). The interaction between tumor cells and
host immune system causes immunoediting (Schreiber et al.,
2011), fosters tumor immune evasion, and ultimately results in
tumor dissemination, relapse, and metastasis (Pardoll, 2012;
Zou, 2005). Tumor-infiltrating T cell subsets (Curiel et al., 2004;
Galon et al., 2006; Page`s et al., 2005; Zhang et al., 2003) have
been extensively studied in human cancers. Myeloid-derived
suppressor cells (MDSCs) are an important immune component
in the tumor microenvironment and are thought to mediate im-
mune suppression in tumor-bearing mice and in patients with
cancer (Bronte and Zanovello, 2005; Gabrilovich and Nagaraj,
2009; Ma et al., 2011). However, MDSCs are poorly defined in
the human cancer microenvironment.
The evolutionarily conservedmicroRNAs are endogenous22
nt noncoding RNAs that fine tune gene expression and regulate
cell differentiation and cell-fate determination (Bartel, 2004; Xiao
and Rajewsky, 2009). MicroRNA expression and function are
linked to cancer development and progression (Korpal et al.,
2011; Liu et al., 2011; Ma et al., 2007; Shimono et al., 2009).
However, the expression, regulation, and potential oncogenic
function of any given microRNA in high-grade ovarian serous
carcinoma remain unclear.
Identification of cancer stem cells (CSCs) (or cancer-initiating
cells) is crucial for advancing cancer biology and therapy.
Several markers including aldehyde dehydrogenase (ALDH)
have been utilized to identify and investigate human epithelial
cancer stem cells (Kryczek et al., 2012; Wicha, 2006). CSCsmunity 39, 611–621, September 19, 2013 ª2013 Elsevier Inc. 611
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Figure 1. MDSCs in Patients with Ovarian
Cancer
Single cells of ovarian cancer tissues were stained
for relevant markers. Doublets and apoptotic cells
were gated out.
(A) Flow cytometry gate of MDSCs. MDSCs were
gated at the basis of their size, localization (FSC/
SSC), and phenotypes (CD45+CD2CD19
CD33+). Arrow pointed to gatedMDSCs. One of 40
cancers is shown.
(B) Percentage of nontumor cells in fresh ovarian
cancer tissues. Results are expressed as themean
percentage + SEM; n = 10.
(C and D) MDSCs mediated immune suppression
in vitro. Autologous T cells were cultured with
MDSCs with different ratios for 3 days. T cell prolif-
eration was determined by thymidine incorporation
(C) and cytokine and granzyme B expression were
analyzed by FACS (D). Results are expressed as the
percent of positive cells in specific T cell subset +
SEM; n = 6, p < 0.01, as compared to controls.
(E) MDSCs mediated immune suppression in vivo.
Autologous TAA-specific T cells were conditioned
with MDSCs and injected into NSG mice bearing
established ovarian cancer. Tumor volume was
measured. One experiment is shown with twomice
per group from one patient donor. Similar experi-
ments were done in three patient donors. n = 6/
group, p < 0.01, as compared to no MDSC and
controls.
See also Figure S1.
Immunity
Effects of MDSCs on Cancer Stemnessare thought to contribute to tumor progression, metastasis, and
therapeutic resistance (Brabletz et al., 2005; Dean et al., 2005;
Pardal et al., 2003; Wicha, 2006). However, the factors that
determine the invasive, metastatic, and chemoresistant pheno-
type of tumor cells are not clear. One concept is that the invasive
tumor phenotype is defined by cell-autonomous alterations
specified by the genomes of cancer cells. Alternatively, metasta-
tic traits may be acquired through interactions between tumor
cells and environmental signals within the tumor microenviron-
ment (Karnoub et al., 2007; Kim et al., 2009; Liu et al., 2011;
Qian et al., 2011). Among environmental signals affecting tumor
cells, the roles of mesenchymal stem cells, macrophages, and
bone-marrow-derived progenitors (Dawson et al., 2009; De-
Nardo et al., 2011; Kaplan et al., 2005; Karnoub et al., 2007;
Kim et al., 2009; Liu et al., 2011; Qian et al., 2011) have largely
been investigated in tumor-bearing mouse models. In this work
we focused on the microenvironment in human primary high-
grade ovarian serous carcinoma and tested our hypothesis
that MDSCs, a crucial immune component in the tumor microen-
vironment, functions as an environmental extrinsic signal,
directly targets CSCs, defines tumor phenotype, and impacts
patient outcome. Thus, we have established a cellular, molecu-
lar, and clinical link among MDSCs, microRNA, CSCs, and pa-
tients with high-grade ovarian serous carcinoma.
RESULTS
Immunological Impact of MDSCs in Ovarian Cancer
High-grade serous carcinoma is the most common histologic
subtype and most lethal among epithelial ovarian carcinomas.612 Immunity 39, 611–621, September 19, 2013 ª2013 Elsevier Inc.This study included only high-grade ovarian serous cancer pa-
tients. We first assessed the immunological relevance of
MDSCs in ovarian cancer. Polychromatic flow cytometry anal-
ysis demonstrated that linCD45+CD33+ cells infiltrated ovarian
tumors (Figure 1A and Figures S1A and S1B available online)
and that these cells comprise 37% of nonneoplastic cells in
the tumor microenvironment (Figure 1B) and expressed medium
levels of HLA-DR (Figure S1A). The majority of these cells were
CD15 and CD16/lo in ovarian cancer (Figure S1A). LinCD45+
CD33+ cells were also found in peripheral blood (Figure S1C).
Sorted tumor-associated (Figure 1C) but not peripheral blood
(Figure S1D) linCD45+CD33+ cells suppressed T cell prolifera-
tion in a dose-dependent manner and inhibited CD4+ and CD8+
T cell effector cytokine interleukin-2 (IL-2) and interferon-g
(IFN-g) expression and granzyme B expression (Figure 1D). To
test the potential direct effect of tumor-associated linCD45+
CD33+ cells on T-cell-mediated antitumor immunity, we utilized
our xenograft tumor model with primary human ovarian cancer
cells (Curiel et al., 2004; Kryczek et al., 2011, 2012). We estab-
lished tumors comprised of primary human ovarian cancer cells
into the dorsal flank of female NOD-Shi-scid-IL-2Rgnull (NSG)
mice and treated the mice with tumor-associated antigen
(TAA)-specific T cells educated or noneducated by tumor-asso-
ciated linCD45+CD33+ cells. We observed that tumor-associ-
ated linCD45+CD33+ cells weakened T-cell-mediated anti-
tumor immunity as shown by enhanced tumor volume when
compared to tumor alone or tumor plus noneducated T cells
(Figures 1E and S1E). Thus, we referred to tumor-associated
linCD45+CD33+ cells as myeloid-derived suppressor cells
(MDSCs).
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Figure 2. Clinical Impact of MDSCs in Pa-
tients with Ovarian Cancer
MDSCs were quantified in primary and metastatic
ovarian cancer. Kaplan-Meier estimates of overall
survival and progression-free interval were per-
formed according to the median values of CD33+
MDSC density. Overall survival (A and C) and
disease-free interval (B and D) in patients with
primary cancer (A and B) and metastatic cancer (C
and D) are shown.
See also Figure S2 and Tables S1 and S2.
Immunity
Effects of MDSCs on Cancer StemnessClinical Impact of MDSCs in Ovarian Cancer
We next examined the clinical relevance of MDSCs in ovarian
cancer patients. Multiple reverse gating polychromatic flow cy-
tometry analysis showed that CD33+ cells were confined to
linCD45+CD33+ MDSCs in fresh ovarian tumor tissue (Fig-
ure S1B). Tumor-associated linCD45+CD33+ MDSCs did not
express CD3, CD19, CD34, and CD56 (Figure S1B). Thus, we
quantified CD33+ cells with immunohistochemistry (Figure S2)
in ovarian tumor tissues from patients whose clinical and patho-
logical information was available (Tables S1 and S2). Based on
the median values of CD33+ MDSC density, we divided patients
into ‘‘low’’ and ‘‘high’’ groups.
Age, tumor stage, and debulking were important prognostic
factors for survival (Table S1). Overall survival (p = 0.006, n =
137, HR = 1.99, 95% CI: 1.22, 3.25) and disease-free interval
(DFI) (p = 0.02, n = 135, HR = 1.75, 95% CI: 1.08, 2.87) were
shorter in patients with high MDSC infiltration after adjusting
for the important clinical prognostic factors (Figures 2A and
2B). This relationship between tumor MDSC content and overall
survival (p = 0.03, n = 28, HR = 2.87, 95% CI: 1.11, 7.42) (Fig-
ure 2C) and DFI (p = 0.02, n = 28, HR = 3.25, 95% CI: 1.21,
9.63) (Figure 2D) remained significant in metastatic cancer.
Therefore, increased tumor MDSC numbers are a significant
and independent predictor for poor survival in ovarian cancer.MDSCs Enhance Cancer Incidence, Metastasis,
and Stemness
MDSCs may support ovarian cancer progression and metas-
tasis. We tested this hypothesis by using our established xeno-
graft tumor model with primary human ovarian cancer cells
(Curiel et al., 2004; Kryczek et al., 2011, 2012). We injected vary-
ing numbers of primary ovarian cancer cells into the NSG mice.Immunity 39, 611–621, SeWe found thatR200,000 primary cancer
cells were needed to reach 100% tumor
incidence. When primary ovarian cancer
cells were cultured (conditioned) with
MDSCs and 100,000 MDSC-conditioned
primary cancer cells were subcutane-
ously inoculated into NSG mice, we
observed that there was 100% tumor
incidence (Figure 3A), and the presence
of MDSCs had no effect on tumor volume
under this condition (Figure S3A). Similar
experiments were performed with titrated
tumor cells. MDSCs clearly increased tu-
mor incidence (Figure S3B). These tumorcells were also intravenously injected into NSGmice. There were
more metastatic foci of tumor in the liver and lungs of mice that
received MDSC-conditioned tumor cells as compared to control
animals that were injected with nonconditioned tumor cells (Fig-
ures 3B, 3C, S3C, and S3D).
We hypothesized that MDSCs may affect cancer stem cell
properties. In support of thishypothesis,MDSCspromoted tumor
sphere formation (Figures 3D and 3E) and enhanced the expres-
sionofmultiple stemcell core gene transcripts (Figure 3F). ALDH+
ovarian epithelial cancer cells are enrichedwith cancer stemcells
(Kryczeket al., 2012).WecoculturedMDSCswithprimary ovarian
cancer cells and found that MDSCs increased ALDH+ cells in the
coculture system (Figure 3G). We performed similar experiments
with peripheral blood linCD45+CD33+ cells (Figures S3E–S3G).
These blood-borne cells had no significant effects on tumor inci-
dence (Figure S3E), stem cell-associated gene expression (Fig-
ure S3F), or sphere formation (Figure S3G). Thus, tumor-associ-
ated MDSCs promote ovarian cancer stemness.
MDSCs Stimulate MicroRNA101 Expression in Ovarian
Cancer
We next investigated the mechanism by which MDSCs enhance
cancer stemness. Certain microRNAs affect tumor progression
and metastasis (Korpal et al., 2011; Liu et al., 2011; Ma et al.,
2007; Shimono et al., 2009). MDSCs may regulate cancer stem-
ness by affecting microRNA expression. To examine this possi-
bility, we conducted microRNA arrays in primary tumor cells
conditioned with tumor-associated linCD45+CD33+ cells
(MDSCs), blood linCD45+CD33+ cells, andmedium. Themicro-
RNA arrays showed that MDSCs differentially affected the
expression of microRNAs as compared to medium and blood
controls (Table S3, Figure S4A). Among the increasedptember 19, 2013 ª2013 Elsevier Inc. 613
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Figure 3. MDSCs Enhance Ovarian Cancer
Incidence, Metastasis, and Stemness
(A–C) Effects of MDSCs on ovarian cancer inci-
dence and metastasis. MDSC-conditioned pri-
mary ovarian cancer cells were subcutaneously (A)
or intravenously (B, C) injected into NSG mice.
Tumor development was monitored. Results are
expressed as the percentage of tumor develop-
ment (A). Tumor liver and lung metastasis was re-
corded. Results are expressed as liver weights (B)
and the numbers of tumor lung foci (C). n = 6/
group; p < 0.05.
(D and E) Effects of MDSCs on cancer sphere
formation. Primary ovarian cancer cells and
MDSCs were cocultured in sphere condition.
Sphere formation assay was performed. Results
are expressed as the fold of increase of sphere
numbers ± SD from six patients with triplicates.
*p < 0.01.
(F) Effects of MDSCs on stem-cell-associated
gene transcripts. Primary ovarian cancer cells
were conditioned with MDSCs. Tumor-stem-cell-
associated gene transcripts were quantified with
real-time PCR and are expressed as the mean
values relative to controls ± SD. Five experiments
with triplicates; *p < 0.01.
(G) Effects of MDSCs on ALDH+ cancer stem cells.
Primary ovarian cancer cells were cultured with
MDSCs for 48 hr. ALDH+ cells are expressed as
the mean percentage ± SD, n = 4, derived from
three different patients. *p < 0.05.
See also Figure S3.
Immunity
Effects of MDSCs on Cancer StemnessmicroRNAs, two (microRNA101 andmicroRNA165) were reliably
enhancedmore than four times byMDSCs as compared to blood
linCD33+CD45+ cells in different arrays (Table S3, Figure S4A).
Therefore, we quantified microRNA101 and microRNA165 in pri-
mary CD133+ ovarian cancer stem cells and cancer sphere cells.
The levels of microRNA101 and microRNA165 expression were
higher in primary CD133+ ovarian cancer stem cells (Figure 4A)
and cancer sphere cells (Figure 4B) than in primary CD133
ovarian cancer cells (Figure 4A) and nonsphere cancer cells (Fig-
ure 4B). However, the levels of microRNA101 were higher than
that of microRNA165 in primary CD133+ ovarian cancer stem
cells (Figure 4A) and cancer sphere cells (Figure 4B). Based on
the data, we assumed that MDSCs might induce microRNA101
expression and in turn regulate cancer stemness. In support of
this possibility, we observed that MDSCs stimulated micro-
RNA101 expression in vitro (Figure 4C) and in vivo (Figure 4D) in
primary ovarian cancer cells. As additional controls, in line with
microRNA arrays (Table S3), MDSCs did not stimulate the
expression of microRNA145, microRNA155, and microRNA200
in primary ovarian cancer cells (FigureS4B).Collectively, the find-
ings suggest that microRNA101 induced by MDSCs may be
important for maintaining ovarian cancer stemness.
MDSCs Enhance Stemness via MicroRNA101
We hypothesized that MDSCs enhance cancer stemness via mi-
croRNA101. In support of this hypothesis, a microRNA101 inhib-
itor blockedMDSC-induced cancer sphere formation (Figure 5A)614 Immunity 39, 611–621, September 19, 2013 ª2013 Elsevier Inc.andmicroRNA101 overexpression stimulated cancer sphere for-
mation (Figures 5B and 5C). The increased capacity of cancer
sphere formation by microRNA101 was visible in the secondary
sphere assay (Figure S5A). Furthermore, microRNA101 overex-
pression had no effect on cancer cell proliferation (Figure S5B),
but enhanced expression of multiple stem cell core genes and
genes associated with epithelial to mesenchymal transition
(EMT) (Figure 5D) increased tumor incidence (Figure 5E) and liver
metastasis (Figure 5F). In further support of the in vivo link among
MDSCs, microRNA101, and cancer stemness in patients, we
observed positive correlations between CD33 transcripts and
microRNA101 (n = 70, p = 0.044, r = 0.26) in snap-frozen primary
ovarian cancer tissues. When we dichotomized microRNA101
levels by a median split and divided the patients into high and
low groups, high levels of microRNA101 were associated with
reduced overall survival (p = 0.041, n = 60, HR = 2.52, 95% CI:
1.07, 6.37) (Figure 5G) and DFI (p = 0.045, n = 65, HR = 1.95,
95% CI: 1.02, 3.75) (Figure 5H). As additional control, we
observed that oncogenesis-associated gene FOXO3a and mi-
croRNA155 had no impact on patient survival (not shown). These
data indicate that MDSCs enhance ovarian cancer stemness by
inducing cancer cell microRNA101 expression.
MicroRNA101 Targets CtBP2 and Controls Stemness
We next investigated howmicroRNA101 regulates cancer stem-
ness. We searched for the predicted microRNA101 target with
potential stemness repressor function (Lewis et al., 2005). There
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MicroRNA101 Expression
(A) The expression of microRNA101 and micro-
RNA615 in CD133+ and CD133 cancer cells.
CD133+ and CD133 primary cancer cells were
sorted from ovarian cancer tissues. MicroRNAs
were quantified by PCR. Three patients with trip-
licates are shown. Results are expressed as the
mean values relative to controls ± SD; p < 0.05 as
compared to CD133 cancer cells.
(B) The expression of microRNA101 and micro-
RNA615 in sphere-forming cancer cells. micro-
RNAs were quantified by PCR in sphere-forming
cells and primary cancer cells. One of five experi-
ments with triplicates is shown. *p < 0.05.
(C) Effects of MDSCs on cancer microRNA101
expression in vitro. Primary ovarian cancer cells
were cultured with MDSCs. Cancer microRNA101 expression was quantified by PCR. Three patients (donors 1–3) with triplicates are shown. p < 0.05 as
compared to controls.
(D) Effects of MDSCs on cancer microRNA101 expression in vivo. Primary ovarian cancer cells andMDSCswere injected into peritoneal cavity of NSGmice. After
24 hr, tumor cells were collected and sorted for microRNA101 detection with quantitative PCR. Three patients with triplicates are shown. p < 0.05 as compared to
controls.
See also Figure S4 and Table S3.
Immunity
Effects of MDSCs on Cancer Stemnesswere eight major corepressor complexes (SWI-SNF, PRC1,
NURD, CoREST, NCoR, PRC2, SIN3, and TLE) (Perissi et al.,
2010). Based on computational analysis with TARGETSCAN
software, we found that two corepressor complexes, CtBP2
(the key CoREST complex gene) and Ezh2 and EED (the key
PRC2 complex genes), were the potential targets of micro-
RNA101. Overexpression of microRNA101 had minimal effects
on PRC2 complex gene Ezh2, Suz12, and EED expression (Fig-
ure S6A). We further investigated CtBP2. There was a defined
target site of microRNA101 at the 30 UTR of CtBP2 (Figure 6A).
CtBP2 is involved in normal stem cell regulation (Tarleton and Le-
mischka, 2010) and prostate cancer development (Thomas et al.,
2008). Thus, we hypothesized that microRNA101 targeted
CtBP2 and controlled cancer stemness. To test this hypothesis,
we cloned the predicted 30 UTR of CtBP2 into a luciferase re-
porter vector. A mutant containing site mutations at the pre-
dicted microRNA101 targeting site was generated as a control
(Figure 6A). Overexpression of microRNA101 in primary ovarian
cancer cells had no effects on cell proliferation (Figure S5B).
Overexpression of microRNA101 decreased the reporter activity
containing wild-type-30 UTR-CtBP2, but not the mutant (Mut-30
UTR-CtBP2) (Figure 6B). In line with this observation, CtBP2 pro-
tein expression levels were decreased in primary ovarian cancer
cells overexpressing microRNA101 as compared with the
scramble control (Figure 6C).
To determine the role of CtBP2 in cancer stemness, CtBP2
expression was genetically knocked down by two specific
small hairpin CtBP2 RNAs (shCtBP2-A, shCtBP2-B) in primary
ovarian cancer cells. CtBP2 silencing had no effects on cancer
cell proliferation (Figure S6B) or tumor growth (Figure S6C)
in vivo, but resulted in increased stem cell core protein expres-
sion (Figure 6D), increased cancer sphere formation (Figure 6E),
and tumor incidence (Figure 6F). ChIP analysis confirmed that
microRNA101 overexpression (Figure 6G) and knock down of
CtBP2 (Figure 6H) resulted in reduced CtBP2 expression and
less occupancy on the promoters of NANOG, OCT4/3, and
SOX2 in primary ovarian cancer cells. Furthermore, MDSCs
increased microRNA101 expression (Figures 4A–4C) andImreduced CtBP2 protein expression in primary cancer cells (Fig-
ure 6I). Thus, microRNA101 targets CtBP2 and controls cancer
stemness.
MDSC and CtBP2 Interaction Impacts Clinical Outcome
To examine the importance of cancer CtBP2 expression, we
quantified the expression of tumor CtBP2 by H-score method
(Supplemental Experimental Procedures and Figure S7) and
analyzed its impact on patient survival. Based on the median
levels of CtBP2 expression (Figure S7), patients were divided
into two groups, low and high CtBP2 expression. High levels of
CtBP2 expression in primary tumor cells were associated with
increased overall survival (p = 0.006, n = 95, HR = 0.41, 95%
CI: 0.21, 0.77) (Figure 7A) and DFI (p = 0.047, n = 93, HR =
0.55, 95% CI: 0.30, 0.98) (Figure 7B).
Finally, we evaluated significance of the two parameters for
ovarian cancer survival. High CD33+ MDSC infiltration strongly
correlated with low CtBP2 expression in primary tumors (n =
96, r = 0.44, p < 0.0001) (Figure 7C), suggesting that MDSCs
may impact patient outcome through controlling CtBP2 expres-
sion. Thus, we reasoned that the patients with high levels of
MDSCs (CD33hi) and low tumor CtBP2 expression (CtBP2lo)
would have had a shorter survival than those with a tumor
type of CD33loCtBP2hi. Indeed, CD33hiCtBP2lo patients experi-
enced a shorter overall survival (p = 0.0018, HR = 3.8, 95% CI:
1.64, 8.79, n = 96) (Figure 7D) and DFI (p = 0.0049, HR = 3.02,
95% CI: 1.40, 6.53, n = 92) (Figure 7E) than did CD33loCtBP2hi
patients, after adjusting for important clinical prognostic fac-
tors. The combination of CtBP2 and MDSCs may allow for
improved prognostic stratification of ovarian cancer overall sur-
vival as compared to CD33 or CtBP2. Based on 96 patients
with both CD33 and CtBP2 values, we found that the hazard
of death for CD33hiCtBP2lo is 3.8 times the hazard of death
for CD33loCtBP2hi (p = 0.0018, HR = 3.80, 95% CI: 1.64,
8.79), compared to 1.99 times with CD33 (high versus low:
p = 0.02, HR = 1.99, 95% CI: 1.22, 3.25) or 2.47 times with
CtBP2 (low versus high: p = 0.006, HR = 2.47, 95% CI: 1.30,
4.71), in addition to age, stage, and debulking. Collectively,munity 39, 611–621, September 19, 2013 ª2013 Elsevier Inc. 615
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Figure 5. MDSCs Promote Cancer Stem-
ness via MicroRNA101
(A) Effect of microRNA101 inhibition on ability of
forming spheres by ovarian cancer cells. Sphere
assays were performed in the presence of MDSCs
and microRNA101 inhibitor. Seven patients with
triplicates are shown. Results are expressed as the
mean values relative to controls ± SD. *p < 0.01 for
testing that the effect of MDSCs depends on mi-
croRNA101.
(B and C) Effects of ectopic microRNA101 on
sphere formation. Sphere assays were performed
in primary ovarian cancer cells transfected with
lentiviral vector encoding microRNA101 and con-
trol. Three patients with triplicates are shown.
Results are expressed as the mean values relative
to controls ± SD. *p < 0.01 as compared to
microRNA vector.
(D) Effects of ectopic microRNA101 on stem-cell-
associated gene transcripts. The relevant genes
were quantified in primary ovarian cancer cells
transfected with lentiviral vector encoding micro-
RNA101 and control. Three experiments with
triplicates are shown. Results are expressed as the
mean values relative to controls ± SD; *p < 0.01 as
compared to microRNA vector.
(E and F) Effects of ectopic microRNA101 on
ovarian cancer incidence and metastasis. Tumor
development was monitored (E). n = 6/group.
Tumor liver metastasis was recorded (F). n = 5/
group. p < 0.05.
(G and H) Clinical relevance of microRNA101. mi-
croRNA101 was quantified by PCR in snap-frozen
primary ovarian cancer. Kaplan-Meier estimates of
overall survival (G) and progression-free interval
(H) were performed according to the median
values of microRNA101.
See also Figure S5.
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Effects of MDSCs on Cancer Stemnessour data support the functional and clinical importance of the
CD33-microRNA101-CtBP2 network in high-grade ovarian se-
rous carcinomas.
DISCUSSION
The tumor microenvironment is a main battle ground between
tumor cells and the host immune system. The capacity of immu-
nity to control and shape cancer including cancer dormancy has
been the subject of intensive investigation (Matsushita et al.,
2012). The interaction between tumor cells and host immune
system causes immunoediting (Dunn et al., 2002), fosters tumor
immune evasion, and ultimately results in tumor dissemination,
relapse, and metastasis (Pardoll, 2012; Zou, 2005). Cancer
stem cells are thought to contribute to tumor progression,
metastasis, and therapeutic resistance (Brabletz et al., 2005;
Dean et al., 2005; Pardal et al., 2003). However, it is not well un-
derstood what determines the invasive, metastatic, and chemo-
resistant phenotype of tumor cells. One concept is that the inva-
sive tumor phenotype is defined by cell-autonomous alterations
specified by the genomes of cancer cells. Alternatively, metasta-616 Immunity 39, 611–621, September 19, 2013 ª2013 Elsevier Inc.tic traits may be acquired through interactions between tumor
cells and environmental signals within the tumor microenviron-
ment (Karnoub et al., 2007; Kim et al., 2009; Liu et al., 2011;
Qian et al., 2011). Among environmental signals affecting tumor
cells, the importance of mesenchymal stem cells, macrophages,
and bone-marrow-derived progenitors (Dawson et al., 2009; De-
Nardo et al., 2011; Kaplan et al., 2005; Karnoub et al., 2007; Kim
et al., 2009; Liu et al., 2011; Qian et al., 2011) have largely been
investigated in tumor-bearing mouse models. However, the ma-
jor immune-suppressive components, MDSCs, are poorly un-
derstood in human cancers. Our current study demonstrates
that MDSCs function as an environmental extrinsic signal,
directly target cancer stem cells, and at least partially shape
tumor phenotype. Thus, cancer stemness is partly defined by im-
mune environmental cues including immune-suppressive
elements.
Here, we isolated viable MDSCs from the microenvironment
of primary ovarian tumors for phenotypic, functional, mecha-
nistic, and clinical studies. We identified high numbers of
immunosuppressive MDSCs in the ovarian tumor microenviron-
ment and showed that MDSCs promote and maintain the
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Figure 6. MicroRNA101 Targets CtBP2 and
Controls Cancer Stemness
(A) Target of microRNA101 in 30 UTR of CtBP2. The
sequence of wild-type (WT) and mutant 30 UTR of
CtPB2 gene used in luciferase assay was shown.
(B) Effect of microRNA101 on WT-30 UTR-CtBP2
luciferase activity. 30 UTR-CtBP2 luciferase activity
was measured in tumor cells transfected with WT-
30 UTR and mutant. Results are expressed as the
percentage of inhibition of 30 UTR-CtBP2 lucif-
erase activity. Three experiments with triplicates
are shown. Results are expressed as the mean
percentage of inhibition ± SEM. *p < 0.01 as
compared to mutant-30 UTR-CtBP2.
(C) Effect of microRNA101 on CtBP2 protein
expression. Primary ovarian cancer cells were
transfected with lentiviral vector encoding micro-
RNA101 and control. Cancer CtBP2 protein was
detected by immunoblotting. One of three experi-
ments is shown.
(D) Effect of CtBP2 on stem cell core protein
expression in primary ovarian cancer cells. Pri-
mary ovarian cancer cells were transfected with
lentiviral vector encoding shCtBP2 and control.
Expression of CtBP2, Nanog, and Sox2 was de-
tected by immunoblotting. ‘‘A’’ and ‘‘B’’ are two
shCtBP2. One of three experiments is shown.
(E) Effect of CtBP2 on ovarian cancer sphere for-
mation. Primary ovarian cancer cells were trans-
fected with lentiviral vector encoding shCtBP2.
Sphere assay was performed in three experiments
with triplicates. Results are expressed as the fold
increase (mean + SEM). *p < 0.01 as compared to
control.
(F) Effect of knock down of CtBP2 expression on
tumor incidence. Primary ovarian cancer cells
were transfected with lentiviral vector encoding
shCtBP2. shCtBP2 cancer cells were injected into
NSG mice. Tumor incidence was monitored. Results are expressed as the percentage of tumor development. n = 6 in control group; n = 5 in sh-CtBP2 group.
p < 0.05.
(G and H) Effects of microRNA101 on the binding of CtBP2 to core stem cell gene promoters. ChIP assay was performed in primary ovarian cancer cells ex-
pressing microRNA101 (G), shCtBP2 (H), or scramble. One of three experiments is shown.
(I) Effect of MDSCs on CtBP2 protein expression in primary ovarian cancer cells. Primary ovarian cancer cells were cultured with MDSCs. CtBP2 protein
expression was detected with immunoblot. One of three experiments is shown.
See also Figure S6.
Immunity
Effects of MDSCs on Cancer Stemnessovarian cancer stem cell pool. Dicer and Drosha mRNA expres-
sion levels in ovarian cancer have associations with outcomes
in patients with ovarian cancer (Merritt et al., 2008). Dicer and
Drosha may control microRNA expression. Aberrant microRNA
expression can contribute to tumorigenesis, tumor progression,
and metastasis (Korpal et al., 2011; Liu et al., 2011; Ma et al.,
2007; Shimono et al., 2009), but it was previously unknown
whether tumor environmental immune elements have any
impact on microRNA expression and function and could in
turn alter the tumor phenotype and patient outcome. We found
that MDSCs stimulate microRNA101 expression in ovarian can-
cer cells and promote cancer stemness by targeting core-
pressor CtBP2. Thus, we have revealed a mechanistic relation-
ship and cross-talk among MDSCs, microRNA101, and CtBP2
at the cellular and molecular levels. We have further demon-
strated the clinical relevance of this cross-talk in ovarian cancer
patients. Our observations suggest that cancer stemness is
partly defined by immune environmental cues. Given the rele-Imvance of cancer stem cells in tumor relapse, metastasis, and
therapy resistance (Brabletz et al., 2005; Dean et al., 2005;
Dontu et al., 2003; Pardal et al., 2003; Reya et al., 2001), our
observations have important consequences for the way in
which we perceive cancer stem cells or MDSCs as indepen-
dent therapeutic targets, shifting the attention from cancer
(stem) cells or immune-suppressive networks (Zou, 2005) to
their interaction in the cancer microenvironment. Given that tu-
mor-infiltrating effector T cells (Galon et al., 2006; Page`s et al.,
2005; Zhang et al., 2003) including Th17 cells (Kryczek et al.,
2009a) are associated with improved survival in patients with
cancer, our data indicate that different immune elements in
the tumor microenvironment may play distinct roles in tumor
progression, metastasis, and therapy, and in turn differentially
affect patient outcome. It is reasonable to predict that anti-
cancer therapy should simultaneously target host MDSCs and
cancer (stem) cells to improve therapeutic efficiency and
reduce therapy resistance.munity 39, 611–621, September 19, 2013 ª2013 Elsevier Inc. 617
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Figure 7. MDSCs and CtBP2 Interaction Im-
pacts Patient Outcome
(A and B) Impact of CtBP2 on patient survival.
CtBP2 expression was quantified in primary
ovarian cancer. Kaplan-Meier estimates of overall
survival (A) and progression-free interval (B) were
performed according to the median levels of
CtBP2 expression.
(C) The association and distribution between
tumor CtBP2 and CD33+ MDSCs in patients with
ovarian carcinoma. Patients were divided into four
groups: CD33loCtBP2hi, CD33loCtBP2lo, CD33hi
CtBP2lo, and CD33hiCtBP2hi. Patient distribution
in four groups and the association between CtBP2
expression levels and CD33+ cell density are
shown.
(D and E) Impact of MDSC and CtBP2 interaction
on ovarian cancer overall survival. Kaplan-Meier
estimates of overall survival (D) and progression-
free interval (E) were performed according to the
median levels of CtBP2 expression and MDSC
intensity.
See also Figure S7.
Immunity
Effects of MDSCs on Cancer StemnessEXPERIMENTAL PROCEDURES
Ovarian Cancer Patients and Cancer Tissue Samples
High-grade serous carcinoma is the most common cancer and most lethal
type of ovarian carcinoma. Patients diagnosed with high-grade serous ovarian
carcinomas were recruited for this study. Human subject use in this study was
approved by the local institutional review boards. We collected 140 formalin-
fixed, paraffin-embedded ovarian tumor tissue blocks, 73 snap-frozen ovarian
tumor tissues, and 40 fresh ovarian cancer tissues for this study as described
previously (Curiel et al., 2003, 2004; Kryczek et al., 2006; Zou et al., 2001). After
pathological review, a tissue microarray (TMA) was constructed from the most
representative area of paraffin-embedded ovarian tumor tissue. For each
tumor, a minimum of two representative tumor areas were selected from a
hematoxylin- and eosin-stained section of a donor block. Core cylinders
(1 mm) were punched from each of these areas and deposited into a recipient
paraffin block. Consecutive 6 mm thick TMA sections were cut and placed on
charged poly-L-lysine-coated slides for immunohistochemistry analyses.
Further information regarding the TMA is described in the Supplemental
Experimental Procedures.
In Vitro and In Vivo T Cell Immunosuppression
In vitro T cell immunosuppression was tested in coculture system. T cells (23
105/ml) were stimulated with 2.5 mg/ml anti-human CD3 and 1.2 mg/ml anti-
CD28 (BD) in the presence of different concentrations of peripheral blood
linCD45+CD33+ cells or MDSCs (2 3 105/ml). At 72 hr after coculture,
T cell proliferation and cytokine production were evaluated as we described
(Curiel et al., 2003, 2004; Kryczek et al., 2006; Zou et al., 2001). The in vivo
T cell suppression was tested with primary ovarian cancer cells in NSG
model. Primary ovarian tumor cells (1 3 107) in 200 ml of buffered saline
were subcutaneously injected into dorsal tissues of female NSG mice. We es-618 Immunity 39, 611–621, September 19, 2013 ª2013 Elsevier Inc.tablished TAA-specific T cells from patients with
HLA-A2+ Her2/neu+ ovarian cancer (Supple-
mental Experimental Procedures; Curiel et al.,
2003, 2004; Kryczek et al., 2006). Autologous
TAA-specific T cells (6 3 106) were conditioned
with MDSCs (3 3 106) or medium and were sub-
sequently injected intravenously into mice on
day 12 after human tumor inoculation (Curiel
et al., 2003, 2004; Kryczek et al., 2006). Tumor
size was measured twice weekly with calipers
fitted with a Vernier scale. Tumor volume wascalculated based on three perpendicular measurements (Curiel et al., 2003,
2004; Kryczek et al., 2006; Zou et al., 2001).
Immunohistochemistry Staining
Immunohistochemical staining on TMA slides was performed on a DAKO
Autostainer (DAKO) with DAKO LSAB+ and diaminobenzadine (DAB) as the
chromogen. Serial sections of deparaffinized TMA sections were labeled
with mouse anti-human CD33 mAb (Clone, NCL-L-CD33, 1:100, Novacastra)
or goat anti-human CtBP2 antibody (SC-5966, 1:500, Santa Cruz Biotech).
Cores from several normal organ tissues were used as tissue controls on
each slide. Staining with isotype antibody was used as negative control.
The cores were quantified and analyzed for the expression of CD33 and
CtBP2 with an Aperio imaging system (Genetix). The specimens were digita-
lized with an automated platform (Aperio Technologies) and ScanScope XT
and Spectrum Plus with TMA software v.9.1 scanning system. Cores were
scored in high resolution of 350. Tissue sections were scored manually on a
computer screen, and a mean score for duplicate cores from each individual
was calculated. Any discrepancies were resolved by subsequent consultation
with diagnostic pathologists. CD33 was localized in the cell membrane/cyto-
plasm and was scored quantitatively (the numbers of positive cells). The tis-
sues were divided into high (>14) and low (<14) CD33+MDSC infiltration based
on the median value of CD33+ cells per 10 mm2. CtBP2 was localized in the
nuclei and was scored by the H score method (Pirker et al., 2012). The tissues
were divided into high and lowCtBP2 expression based on themedian value of
CtBP2 expression level per core. The H score is a method of assessing the
extent of nuclear immunoreactivity. The H score takes into account the per-
centage of positive cells (0%–100%) in each intensity category (0–3+) and
computes a final score on a continuous scale between 0 and 300. The score
is obtained by the formula: 3 3 percentage of strongly staining nuclei + 2 3
percentage of moderately staining nuclei + percentage of weakly staining
Immunity
Effects of MDSCs on Cancer Stemnessnuclei, giving a range of 0 to 300 (Pirker et al., 2012). The tissues were divided
into high and low CtBP2 expression based on the median value of CtBP2
expression level per core. Cores from normal breast, heart, thyroid, and tonsil
tissues were used as control on each slide. Staining with isotype antibody was
used as negative control.
Quantitative Real-Time PCR to Detect MicroRNA and mRNA
Expression
Total RNA was isolated from frozen tumor tissue or primary tumor cells with
Trizol Reagent (Invitrogen). MicroRNAs were detected by TaqMan MicroRNA
Assay kit (Applied Biosystems). Quantitative real-time PCR was carried out
to quantify stem-cell- and EMT-associated genes (Kryczek et al., 2011).
Tumor MDSC and Cancer Stem Cell Identification and Isolation
Fresh ovarian cancer tissues were processed into single-cell suspensions and
immediately used for cellular phenotyping by a flow cytometry analyzer (LSR II,
Becton Dickinson) or flow sorting by high-speed sorter (FACSAria, BD) as
described (Curiel et al., 2004; Kryczek et al., 2011). Antibodies against CD2,
CD3, CD4, CD15, CD16, CD19, CD33, CD45, CD133, and epithelial cell adhe-
sion molecule (EpCAM) were used in the flow experiments (BD Biosciences)
(Kryczek et al., 2012). The purity of the sorted cells was >98%.
Ovarian Cancer Development and Metastasis in NSG Model
Experimentally manipulated primary ovarian cancer cells were cultured with
autologous tumor-associated MDSCs and then sorted to high purity (>99%)
or were stably transfected with specific gene vectors, and were subcutane-
ously or intravenously injected into female NOD-Shi-scid-IL-2Rgnull (NSG)
mice (6–8 weeks old; Jackson Laboratory). The viability of the injected tumor
cells was >95%. Subcutaneous tumors were measured every 3 days via a
caliper scale, and tumor volume was calculated based on three perpendicular
measurements as described (Kryczek et al., 2011, 2012). On day 50 after injec-
tion, liver weight and tumor metastatic foci were recorded. Lung metastases
were ink stained and counted (Kryczek et al., 2009b). In some cases, primary
tumor cells and MDSCs were injected into the peritoneal cavity of mice. After
24 hr, tumor cells were collected and sorted for microRNA101 detection with
quantitative PCR. The animal protocol was approved by the University ofMich-
igan Committee on Use and Care of Animals (UCUCA).
Cell Culture, MicroRNA Array, and In Vitro Sphere Formation
Primary ovarian cancer cells were isolated as described previously (Kryczek
et al., 2012). Primary ovarian cancer cells were initially cultured with freshly iso-
lated MDSCs in trans-wells (Corning) and were subsequently harvested for
microRNA array (Applied Biosystems, Cat# 4470187), quantitative PCR,
sphere formation assay (Kryczek et al., 2012), and in vivo experiments.
MicroRNA Array
Primary ovarian cancer cells (5 3 105) were cocultured with freshly sorted
ovarian-cancer-associated MDSCs, peripheral blood linCD45+CD33+ cells
(5 3 105), or medium in a transwell (Corning) for 24 hr. Then, RNA was ex-
tracted from the cancer cells by Trizol reagent. The RNAs were applied for
microRNA profiling via OpenArray system (Applied Biosystems, Cat#
4470187) (Mestdagh et al., 2008) at University of Michigan Sequencing Core.
Gene Transfection and 30 UTR-CtBP2 Reporter Dual Luciferase
Assay
Primary ovarian cancer cells stably expressing microRNA101 or microRNA
scramble were established with lentivirus packaging kit (Invitrogen) by means
of microRNA101 and control plasmids (Biosettia Inc). Primary ovarian cancer
cells stably expressing shCtBP2 or scramble control were established by us-
ing shCtBP2 or control pGIPZ-GFP plasmids with puromycin selection (Open
Biosystem, University of Michigan Vector Core). In some experiments, primary
ovarian cancer cells were transiently transfected with microRNA101 inhibitor
or control oligonucleotides (100 mM, Thermo Fisher Scientific Dharmacon
Products) 24 hr before functional experiments (Vilardo et al., 2010).
The PCR fragment of 30 UTR of CtBP2 (926–1,325 bp) containing a predicted
microRNA101 targeting site (1109–1115) was cloned into a pMIR luciferase re-
porter (Applied Biosystems) at SpeI and HidIII cloning sites by using human
genomic DNA template prepared from normal human peripheral blood mono-Imnuclear cells. Four site mutations were created at the predicted microRNA101
targeting site by means of a mutagenesis kit (Promega Biosystems). The wild-
type (WT)-30 UTR-CtBP2 or mutant (Mut)-30 UTR-CtBP2 reporter plasmids
were transiently expressed in primary ovarian cancer cells along with micro-
RNA101 and control plasmids by Lipo2000. pTK-renilla was transfected as
an internal control in each transfection. At 48 hr after the transfection, cell
lysates were applied for dual luciferase activity measurement with the dual
luciferase kit (Promega) and a luminometer. RLU represented as CtBP2 30
UTR luciferase activity related to its renilla luciferase activity. The experiments
were repeated three times with triplicates.
Immunoblot and Chromatin Immunoprecipitation
Immunoblotting was performed with the following primary antibodies: CtBP2
(1:1,000, 612044, BD), NANOG (1:1,000, ab21624, Abcam), SOX2 (1:1,000,
MAB4343, Millipore), and a-TUBULIN (1:2,000, Santa Cruz). Signals were de-
tected by ECL reagent (GE Healthcare).
ChIP was performed as we described (Cui et al., 2008). In brief, nuclear ex-
tracts were prepared from primary ovarian cancer cells. Mouse anti-human
CtBP2 (BD) and normal IgG (Santa Cruz) antibodies were used for immunopre-
cipitation. ChIP primers (Table S4) were designed to detect promoter fragment
near transcription start sites on OCT4/3, NANOG, and SOX2.
Statistical Analysis
Wilcoxon rank-sum tests were used to compare two independent groups, and
for paired groups, Wilcoxon signed rank tests were used for the comparison.
Correlation coefficients (Spearman correlation [denoted by r] for ordinal data
and Pearson correlation [denoted by r] for continuous data) together with a
p value (null hypothesis is that r is in fact zero) were computed to measure
the degree of association between biomarkers. ANOVA models were used
to evaluate an interaction between MDSCs and microRNA101 on cancer
sphere formation. Log-rank test was used to compare time to tumor initiation
between two groups. Overall patient survival was defined from date of diag-
nosis to disease-related death. Disease-free interval was defined from date
of diagnosis to disease progression or disease-related death. Data were
censored at the last follow-up for patients who were disease-free or alive at
the time of analysis. Survival functions were estimated by Kaplan-Meier
methods. Cox’s proportional hazards regression was performed to model sur-
vival as a function of MDSC, CtBP2, and microRNA101 (all classified as low
and high based on the median value) or the combination of MDSC and
CtBP2 (classified as MDSCloCtBP2hi and MDSChiCtBP2lo) after adjusting for
age, stage, and debulking. We assessed the adequacy of the Cox regression
model; graphical and numerical methods are as described (Lin et al., 1993). All
analyses were done with SAS 9.3 software. p < 0.05 considered as significant.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE50082.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Experimental Procedures, seven figures,
and four tables and can be found with this article online at http://dx.doi.org/
10.1016/j.immuni.2013.08.025.
ACKNOWLEDGMENTS
This work is supported (in part) by the National Institutes of Health grants
(CA123088, CA099985, CA156685, CA171306, 5P30CA46592), the Ovarian
Cancer Research Fund, and Marsha Rivkin Center for Ovarian Cancer
Research. We thank D. Postiff, M. Vinco, R. Craig, and J. Barikdar in the tissue
procurement core for their technical assistance.
Received: January 10, 2013
Accepted: June 24, 2013
Published: September 5, 2013munity 39, 611–621, September 19, 2013 ª2013 Elsevier Inc. 619
Immunity
Effects of MDSCs on Cancer StemnessREFERENCES
Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and func-
tion. Cell 116, 281–297.
Brabletz, T., Jung, A., Spaderna, S., Hlubek, F., and Kirchner, T. (2005).
Opinion: migrating cancer stem cells - an integrated concept of malignant
tumour progression. Nat. Rev. Cancer 5, 744–749.
Bronte, V., and Zanovello, P. (2005). Regulation of immune responses by
L-arginine metabolism. Nat. Rev. Immunol. 5, 641–654.
Cui, T.X., Kwok, R., and Schwartz, J. (2008). Cooperative regulation of endog-
enous cAMP-response element binding protein and CCAAT/enhancer-binding
protein beta in GH-stimulated c-fos expression. J. Endocrinol. 196, 89–100.
Curiel, T.J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R.,
Knutson, K.L., Daniel, B., Zimmermann, M.C., et al. (2003). Blockade of B7-H1
improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9,
562–567.
Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-
Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., et al. (2004). Specific
recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege
and predicts reduced survival. Nat. Med. 10, 942–949.
Dawson, M.R., Duda, D.G., Fukumura, D., and Jain, R.K. (2009). VEGFR1-
activity-independent metastasis formation. Nature 461, E4, discussion E5.
Dean, M., Fojo, T., and Bates, S. (2005). Tumour stem cells and drug resis-
tance. Nat. Rev. Cancer 5, 275–284.
DeNardo, D.G., Brennan, D.J., Rexhepaj, E., Ruffell, B., Shiao, S.L., Madden,
S.F., Gallagher, W.M., Wadhwani, N., Keil, S.D., Junaid, S.A., et al. (2011).
Leukocyte complexity predicts breast cancer survival and functionally regu-
lates response to chemotherapy. Cancer Discov. 1, 54–67.
Dontu, G., Al-Hajj, M., Abdallah, W.M., Clarke, M.F., and Wicha, M.S. (2003).
Stem cells in normal breast development and breast cancer. Cell Prolif.
36(Suppl 1 ), 59–72.
Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D. (2002).
Cancer immunoediting: from immunosurveillance to tumor escape. Nat.
Immunol. 3, 991–998.
Gabrilovich, D.I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as
regulators of the immune system. Nat. Rev. Immunol. 9, 162–174.
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-
Page`s, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006). Type,
density, and location of immune cells within human colorectal tumors predict
clinical outcome. Science 313, 1960–1964.
Kaplan, R.N., Riba, R.D., Zacharoulis, S., Bramley, A.H., Vincent, L., Costa, C.,
MacDonald, D.D., Jin, D.K., Shido, K., Kerns, S.A., et al. (2005). VEGFR1-pos-
itive haematopoietic bone marrow progenitors initiate the pre-metastatic
niche. Nature 438, 820–827.
Karnoub, A.E., Dash, A.B., Vo, A.P., Sullivan, A., Brooks, M.W., Bell, G.W.,
Richardson, A.L., Polyak, K., Tubo, R., and Weinberg, R.A. (2007).
Mesenchymal stem cells within tumour stroma promote breast cancer metas-
tasis. Nature 449, 557–563.
Kim, S., Takahashi, H., Lin, W.W., Descargues, P., Grivennikov, S., Kim, Y.,
Luo, J.L., and Karin, M. (2009). Carcinoma-produced factors activate myeloid
cells through TLR2 to stimulate metastasis. Nature 457, 102–106.
Korpal, M., Ell, B.J., Buffa, F.M., Ibrahim, T., Blanco, M.A., Celia`-Terrassa, T.,
Mercatali, L., Khan, Z., Goodarzi, H., Hua, Y., et al. (2011). Direct targeting of
Sec23a bymiR-200s influences cancer cell secretome and promotesmetasta-
tic colonization. Nat. Med. 17, 1101–1108.
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M.,
Cheng, P., Curiel, T., Myers, L., et al. (2006). B7-H4 expression identifies a
novel suppressive macrophage population in human ovarian carcinoma.
J. Exp. Med. 203, 871–881.
Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E.,
Finlayson, E., Simeone, D., Welling, T.H., et al. (2009a). Phenotype, distribu-
tion, generation, and functional and clinical relevance of Th17 cells in the
human tumor environments. Blood 114, 1141–1149.620 Immunity 39, 611–621, September 19, 2013 ª2013 Elsevier Inc.Kryczek, I., Wei, S., Szeliga, W., Vatan, L., and Zou, W. (2009b). Endogenous
IL-17 contributes to reduced tumor growth and metastasis. Blood 114,
357–359.
Kryczek, I., Zhao, E., Liu, Y., Wang, Y., Vatan, L., Szeliga, W., Moyer, J.,
Klimczak, A., Lange, A., and Zou, W. (2011). Human TH17 cells are long-lived
effector memory cells. Sci. Transl. Med. 3, ra100.
Kryczek, I., Liu, S., Roh, M., Vatan, L., Szeliga, W., Wei, S., Banerjee, M., Mao,
Y., Kotarski, J., Wicha, M.S., et al. (2012). Expression of aldehyde dehydroge-
nase and CD133 defines ovarian cancer stem cells. Int. J. Cancer 130, 29–39.
Lewis, B.P., Burge, C.B., and Bartel, D.P. (2005). Conserved seed pairing,
often flanked by adenosines, indicates that thousands of human genes are
microRNA targets. Cell 120, 15–20.
Lin, D.Y., Wei, L.J., and Ying, Z. (1993). Checking the Cox model with cumula-
tive sums of martingale-based residuals. Biometrika 80, 557–572.
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L.,
Yan, H., Jeter, C., Honorio, S., et al. (2011). The microRNA miR-34a inhibits
prostate cancer stem cells and metastasis by directly repressing CD44. Nat.
Med. 17, 211–215.
Ma, L., Teruya-Feldstein, J., and Weinberg, R.A. (2007). Tumour invasion and
metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682–688.
Ma, G., Pan, P.Y., Eisenstein, S., Divino, C.M., Lowell, C.A., Takai, T., and
Chen, S.H. (2011). Paired immunoglobin-like receptor-B regulates the sup-
pressive function and fate of myeloid-derived suppressor cells. Immunity 34,
385–395.
Matsushita, H., Vesely, M.D., Koboldt, D.C., Rickert, C.G., Uppaluri, R.,
Magrini, V.J., Arthur, C.D., White, J.M., Chen, Y.S., Shea, L.K., et al. (2012).
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer im-
munoediting. Nature 482, 400–404.
Merritt, W.M., Lin, Y.G., Han, L.Y., Kamat, A.A., Spannuth, W.A., Schmandt,
R., Urbauer, D., Pennacchio, L.A., Cheng, J.F., Nick, A.M., et al. (2008).
Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J.
Med. 359, 2641–2650.
Mestdagh, P., Feys, T., Bernard, N., Guenther, S., Chen, C., Speleman, F., and
Vandesompele, J. (2008). High-throughput stem-loop RT-qPCR miRNA
expression profiling using minute amounts of input RNA. Nucleic Acids Res.
36, e143.
Page`s, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R.,
Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005). Effector
memory T cells, early metastasis, and survival in colorectal cancer. N. Engl.
J. Med. 353, 2654–2666.
Pardal, R., Clarke, M.F., and Morrison, S.J. (2003). Applying the principles of
stem-cell biology to cancer. Nat. Rev. Cancer 3, 895–902.
Pardoll, D.M. (2012). The blockade of immune checkpoints in cancer immuno-
therapy. Nat. Rev. Cancer 12, 252–264.
Perissi, V., Jepsen, K., Glass, C.K., and Rosenfeld, M.G. (2010).
Deconstructing repression: evolving models of co-repressor action. Nat.
Rev. Genet. 11, 109–123.
Pirker, R., Pereira, J.R., von Pawel, J., Krzakowski, M., Ramlau, R., Park, K., de
Marinis, F., Eberhardt, W.E., Paz-Ares, L., Sto¨rkel, S., et al. (2012). EGFR
expression as a predictor of survival for first-line chemotherapy plus cetuxi-
mab in patients with advanced non-small-cell lung cancer: analysis of data
from the phase 3 FLEX study. Lancet Oncol. 13, 33–42.
Qian, B.Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L.R., Kaiser,
E.A., Snyder, L.A., and Pollard, J.W. (2011). CCL2 recruits inflammatorymono-
cytes to facilitate breast-tumour metastasis. Nature 475, 222–225.
Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001). Stem cells,
cancer, and cancer stem cells. Nature 414, 105–111.
Schreiber, R.D., Old, L.J., and Smyth, M.J. (2011). Cancer immunoediting:
integrating immunity’s roles in cancer suppression and promotion. Science
331, 1565–1570.
Shimono, Y., Zabala, M., Cho, R.W., Lobo, N., Dalerba, P., Qian, D., Diehn, M.,
Liu, H., Panula, S.P., Chiao, E., et al. (2009). Downregulation of miRNA-200c
links breast cancer stem cells with normal stem cells. Cell 138, 592–603.
Immunity
Effects of MDSCs on Cancer StemnessTarleton, H.P., and Lemischka, I.R. (2010). Delayed differentiation in embry-
onic stem cells and mesodermal progenitors in the absence of CtBP2.
Mech. Dev. 127, 107–119.
Thomas, G., Jacobs, K.B., Yeager, M., Kraft, P., Wacholder, S., Orr, N., Yu, K.,
Chatterjee, N.,Welch, R., Hutchinson, A., et al. (2008). Multiple loci identified in
a genome-wide association study of prostate cancer. Nat. Genet. 40,
310–315.
Vilardo, E., Barbato, C., Ciotti, M., Cogoni, C., and Ruberti, F. (2010).
MicroRNA-101 regulates amyloid precursor protein expression in hippocam-
pal neurons. J. Biol. Chem. 285, 18344–18351.
Wicha, M.S. (2006). Cancer stem cells and metastasis: lethal seeds. Clin.
Cancer Res. 12, 5606–5607.ImXiao, C., and Rajewsky, K. (2009). MicroRNA control in the immune system:
basic principles. Cell 136, 26–36.
Zhang, L., Conejo-Garcia, J.R., Katsaros, D., Gimotty, P.A., Massobrio, M.,
Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M.N.,
et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian
cancer. N. Engl. J. Med. 348, 203–213.
Zou, W. (2005). Immunosuppressive networks in the tumour environment and
their therapeutic relevance. Nat. Rev. Cancer 5, 263–274.
Zou, W., Machelon, V., Coulomb-L’Hermin, A., Borvak, J., Nome, F., Isaeva,
T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001).
Stromal-derived factor-1 in human tumors recruits and alters the function of
plasmacytoid precursor dendritic cells. Nat. Med. 7, 1339–1346.munity 39, 611–621, September 19, 2013 ª2013 Elsevier Inc. 621
